Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
depression save search
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
ATAI | $1.87 -5.08% -5.07% 840K
|
Manufacturing
|
| O: -1.01%
H: 0.0%
C: -4.59%
bpl-003 first life depression treatment sciences study
Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plus™, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)
Published: 2024-04-23 (Crawled : 00:00) - biospace.com/
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
first drug authorized food depression treatment clearance for therapeutics
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
NBIX | News 4 | $138.97 -0.8% -0.85% 930K
|
Health Technology
|
| O: 5.49%
H: 2.84%
C: -0.65%
nbi-1065 positive for
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
ITCI 4 d | $73.12 -1.2% -1.36% 740K
|
Health Technology
|
| O: 14.75%
H: 12.75%
C: 6.04%
positive topline therapy results study
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Published: 2024-04-09 (Crawled : 14:30) - biospace.com/
VTGN | $4.72 -2.28% -1.68% 150K
|
Health Technology
|
| O: 0.58%
H: 3.65%
C: 3.27%
conference association depression
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MYGN | $18.63 0.16% 0.05% 480K
|
Health Technology
|
| O: 0.44%
H: 3.39%
C: 2.5%
depression genesight research for
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-04-08 (Crawled : 12:30) - prnewswire.com
NRXP 5 d | $3.12 2.3% 1.93% 98K
|
Manufacturing
|
| O: 0.57%
H: 7.01%
C: 3.79%
nrx-101 depression treatment pharmaceuticals trial
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Published: 2024-04-03 (Crawled : 14:30) - biospace.com/
NBIX | News 4 | $138.97 -0.8% -0.85% 930K
|
Health Technology
|
| O: -0.01%
H: 1.79%
C: -0.09%
nbi-1070 study
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
Published: 2024-04-03 (Crawled : 12:30) - globenewswire.com
BICX | $0.82 9.33% 201.91% 7.5K
|
Health Care and Social Assistan...
|
| O: 7.53%
H: 16.0%
C: 15.0%
patent treat pharmaceuticals schizophrenia
Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
REUN | $1.12 -0.89% 0
|
Health Care and Social Assistan...
| Email alert
Add to watchlist
america conference association depression
BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
BWAY | $5.03 1.93% 1.89% 26K
|
Health Technology
|
| O: -0.19%
H: 3.15%
C: 0.95%
positive depression results
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
Published: 2024-03-27 (Crawled : 13:00) - globenewswire.com
CMND | $1.21 -1.68% 31K
|
n/a
|
| O: 0.0%
H: 1.75%
C: 1.75%
SPRC | $1.21 -1.63% -1.23% 75K
|
Manufacturing
|
| O: -3.23%
H: 0.56%
C: -3.33%
patent depression international application
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
Published: 2024-03-27 (Crawled : 13:00) - globenewswire.com
CMND | $1.21 -1.68% 31K
|
n/a
|
| O: 0.0%
H: 1.75%
C: 1.75%
SPRC | $1.21 -1.63% -1.23% 75K
|
Manufacturing
|
| O: -3.23%
H: 0.56%
C: -3.33%
patent depression international collaboration application
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
ATAI | $1.87 -5.08% -5.07% 840K
|
Manufacturing
|
| O: 4.05%
H: 1.11%
C: -0.56%
bpl-003 label life positive depression treatment sciences results study
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
Published: 2024-03-25 (Crawled : 12:30) - globenewswire.com
STIM | $3.75 -2.85% -2.66% 21K
|
Health Technology
|
| O: 13.48%
H: 3.96%
C: -1.88%
neurostar fda depression treatment clearance advanced therapy
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
AXSM | $71.17 -2.61% -2.6% 580K
|
Health Technology
|
| O: 0.84%
H: 5.95%
C: 5.09%
treatment trial therapeutics solriamfetol
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | $0.355 -0.85% 3.3M
|
n/a
|
| O: 7.14%
H: 5.53%
C: -4.67%
cyb003 fda positive meeting program design
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
Published: 2024-03-11 (Crawled : 19:00) - prnewswire.com
INVVY | $21.8455 19.02% 8.1K
|
n/a
| Email alert
Add to watchlist
opvee respiratory depression publication spray study
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-03-04 (Crawled : 13:30) - prnewswire.com
NRXP 5 d | $3.12 2.3% 1.93% 98K
|
Manufacturing
|
| O: -1.85%
H: 27.88%
C: 20.93%
nrx-101 depression treatment pharmaceuticals trial
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
BETR | $0.4226 1.59% 1.61% 410K
|
n/a
|
| O: 0.0%
H: 1.17%
C: -4.32%
BETRF | $0.0719 -3.49% -3.71% 21K
|
Health Technology
|
| O: 4.91%
H: 2.71%
C: 2.71%
depression treatment
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.